Flag of the European Union EU Clinical Trials Register Help

Clinical trials for alopecia areata

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43387   clinical trials with a EudraCT protocol, of which   7179   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: alopecia areata. Displaying page 1 of 1.
    EudraCT Number: 2021-000387-30 Sponsor Protocol Number: CP543.3002 Start Date*: 2021-07-07
    Sponsor Name:Concert Pharmaceuticals, Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA
    Medical condition: MODERATE TO SEVERE ALOPECIA AREATA IN ADULT PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002365-18 Sponsor Protocol Number: CP543.5002 Start Date*: 2021-12-06
    Sponsor Name:Concert Pharmaceuticals, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA
    Medical condition: MODERATE TO SEVERE ALOPECIA AREATA IN ADULT PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002704-40 Sponsor Protocol Number: CP543.3001 Start Date*: 2021-03-26
    Sponsor Name:Concert Pharmaceuticals, Inc
    Full Title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP- 543 in Adult Patients with Moderate to Severe Alopecia Areata
    Medical condition: Moderate to severe alopecia areata in adult patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000659-18 Sponsor Protocol Number: FumadermAA01 Start Date*: 2011-08-22
    Sponsor Name:University Hospital Tübingen
    Full Title: Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003208-30 Sponsor Protocol Number: RAAINBOW Start Date*: 2017-11-14
    Sponsor Name:Legacy Healthcare (France) SAS
    Full Title: Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp alopecia ar...
    Medical condition: Alopecia Areata
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) BG (Ongoing) FR (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001084-71 Sponsor Protocol Number: B7981032 Start Date*: 2020-06-01
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, New York
    Full Title: A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Ongoing) HU (Completed) PL (Ongoing) DE (Restarted) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001714-14 Sponsor Protocol Number: B7981015 Start Date*: 2019-07-22
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR...
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002720-24 Sponsor Protocol Number: EXP-1377 Start Date*: 2017-10-17
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a
    Medical condition: Alopecia Areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001509-21 Sponsor Protocol Number: B7981037 Start Date*: 2020-12-08
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-000328-16 Sponsor Protocol Number: 20170588 Start Date*: 2019-09-23
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) FR (Ongoing) PT (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003509-72 Sponsor Protocol Number: 20200234 Start Date*: 2021-10-21
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GR (Ongoing) PL (Ongoing) AT (Ongoing) BG (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA